Epithelial Ovarian Tumor of Borderline Malignancy

Other names
Types
Causes and risk factors
Symptoms
Diagnostic tests
Non-pharmacological treatments (therapies & other measures)
Drug treatments
Dietary molecular supplements
Drugs forimmunity booster / regenerative / stem-cell
Surgeries (what is done and why)
Preventions
When to see a doctor (red flags)
What to eat and what to avoid
FAQs

A Epithelial Ovarian Tumor of Borderline Malignancy is a growth that starts from the surface lining (epithelium) of the ovary. The cells look more abnormal than a benign cyst, but they do not invade the surrounding tissue like cancer cells do. Doctors also call this “low malignant potential.” It sits between benign and cancer on a spectrum. Under the microscope, the pathologist sees strong cell crowding and atypia, but no destructive stromal invasion. That absence of invasion is the key feature that makes it “borderline.” Most patients are diagnosed at an early stage. Outcomes are usually good, especially when the tumor is confined to one or both ovaries. Some serous borderline tumors can seed the peritoneum with implants; these implants may be non-invasive or, less often, invasive and need careful expert review. esgo.org+3whobluebooks.iarc.who.int+3Meridian+3

A borderline ovarian tumor is a growth that starts from the surface lining (epithelium) of an ovary. Under the microscope, the cells look more abnormal than a simple benign cyst, but they do not invade the surrounding tissue the way true cancer does. Because there is little or no invasion, these tumors behave much less aggressively than regular ovarian cancer. Most people do very well after surgery, and long-term survival is high. Some patients can keep child-bearing ability with carefully chosen fertility-sparing surgery. Follow-up is important because a minority can recur or rarely transform. Decisions depend on tumor type (serous, mucinous, others), stage, implants, and your goals for fertility. Dove Medical Press+2PMC+2

Borderline tumors are part of the World Health Organization (WHO) classification of tumors of the female genital tract. In the current WHO system (5th ed.), the main borderline categories include serous and mucinous; endometrioid borderline tumors exist but are rare. The prior “seromucinous” category has been largely abandoned or re-assigned in the new scheme. Precise diagnosis depends on detailed sampling by a pathologist. whobluebooks.iarc.who.int+1

Most borderline tumors present in younger women than invasive ovarian cancer. Many are found around age 40, and many are stage I at diagnosis. This is one reason fertility-sparing surgery can be considered in selected cases. NCBI

Other names

Borderline ovarian tumor (BOT)
Low malignant potential (LMP) ovarian tumor
Atypical proliferative epithelial ovarian tumor
All of these terms describe the same family of tumors with epithelial atypia but no stromal invasion. Wikipedia

Types

Serous borderline tumor (SBT)
This is the most common type. It may have papillary fronds and sometimes “micropapillary” patterns. It can be bilateral. Some patients have peritoneal implants that need expert classification as non-invasive vs invasive. PMC+1
Mucinous borderline tumor (MBT)
Second most common. Many are large, often unilateral. Pathology separates “intestinal-type” from “endocervical-type” features. Correct sampling is essential to rule out small foci of invasion. Meridian
Endometrioid borderline tumor (rare)
Uncommon; can be associated with endometriosis. Diagnosis requires WHO criteria and exclusion of invasion. Meridian

(Note on terminology): WHO 5th ed. refined categories and discouraged “seromucinous” as a stand-alone entity; most such lesions are re-classified after full review. Always rely on final pathology using WHO 5th ed. definitions. Meridian

Causes and risk factors

No single cause explains all BOTs. Risk factors overlap with epithelial ovarian cancer, but strength of association can differ by histology.

Age around reproductive years – BOTs are often found in women in their 30s–40s, younger than typical invasive ovarian cancer. NCBI
Ovulation lifetime exposure – More ovulations across life may raise epithelial proliferation and risk. Parity and oral contraceptives reduce lifetime ovulations and may reduce risk. Cancer.gov
Infertility and ART (assisted reproduction) – Some large studies suggest a higher risk of BOTs after some fertility treatments; the absolute risk is still low. PMC+2MDPI+2
Endometriosis (especially for endometrioid-type) – Endometriosis is linked to certain epithelial ovarian tumors; the link with BOTs is less strong than with invasive endometrioid or clear cell, but association exists in some series. PMC+2ScienceDirect+2
Cigarette smoking (especially mucinous BOT) – Smoking is consistently linked to mucinous ovarian tumors, including borderline mucinous tumors. PMC+2Nature+2
Family history of ovarian/breast cancer – High-penetrance BRCA mutations are less clearly tied to BOTs than to high-grade serous cancer, but family clustering can occur. Cancer.gov
Early menarche / late menopause – More ovulatory cycles may raise risk. Cancer.gov
Nulliparity – Having no births is associated with a higher lifetime ovulation count. Cancer.gov
Short or no use of combined oral contraceptives – Pills suppress ovulation and may lower epithelial ovarian tumor risk. Cancer.gov
Hormone therapy (estrogen-only, postmenopause) – Some data show a small increased risk of epithelial tumors; the link to BOT is not as well defined but is considered in risk discussions. Cancer.gov
Obesity – Adipose tissue raises estrogen and inflammation; risk signals vary by histology but may increase epithelial tumor risk overall. Cancer.gov
Pelvic inflammatory disease history – Chronic inflammation may contribute to epithelial change in some women. Cancer.gov
Talc use on the perineum (controversial) – Some epidemiologic studies show association with epithelial ovarian tumors; causality is uncertain. Cancer.gov
Genetic variants beyond BRCA (e.g., Lynch in general ovarian risk) – BOT is not a classic Lynch phenotype, but any strong family syndrome raises vigilance. bgcs.org.uk
Endometrioma (chocolate cyst) background – Rarely, atypical epithelium can arise in this setting. PMC
Prior pelvic surgery/ovarian stimulation – Hypothesized mechanical or hormonal effects; evidence is mixed. PMC
Environmental exposures – Long-term, low-grade exposures may act with other risks; evidence remains limited. Cancer.gov
Low parity / later first birth – Fewer total pregnancies may raise lifetime ovulatory cycles. Cancer.gov
PCOS with chronic anovulation (complex) – PCOS changes risk patterns; data are mixed, but metabolic features can influence overall gynecologic risk. Cancer.gov
Personal history of some epithelial tumors – Shared pathways (e.g., KRAS/BRAF in mucinous/serous borderline) may reflect epithelial susceptibility. Molecular testing helps classification rather than predicting risk. Meridian

Symptoms

Many women have mild or vague symptoms. Early tumors often cause none.

Bloating or abdominal fullness – A growing cyst makes the belly feel full or tight. NCBI
Pelvic or lower abdominal pain – Stretching of the ovarian capsule or torsion risk can hurt. NCBI
A new pelvic mass or lump – Sometimes felt by the patient or during a pelvic exam. NCBI
Early satiety – Feeling full quickly due to pressure on the stomach. NCBI
Urinary frequency – A large cyst presses on the bladder. NCBI
Constipation – Mass effect on the bowel. NCBI
Irregular bleeding – Less common; can occur from hormonal fluctuations or coexisting uterine issues. NCBI
Back pain – Referred pain from pelvic pressure. NCBI
Dyspareunia (pain with sex) – A tender adnexal mass can cause deep pelvic pain. NCBI
Increase in waist size – Cyst enlargement or fluid (ascites) can enlarge the abdomen. NCBI
Acute severe pain – May reflect torsion, rupture, or bleeding into the cyst; this is an emergency. NCBI
Unintentional weight change – From fluid shifts or decreased appetite. NCBI
Shortness of breath – Rare; large ascites or pleural fluid can cause this in advanced disease. NCBI
Fatigue – Non-specific but common with chronic symptoms. NCBI
Infertility or subfertility history – Sometimes the tumor is found during infertility work-up. PMC

Diagnostic tests

Below are practical tests grouped the way clinicians think in clinic and the operating room. Together they help confirm a mass, gauge risk, plan surgery, and finalize the diagnosis with pathology.

A) Physical examination

General exam and vital signs
The doctor checks weight, temperature, pulse, and blood pressure. The goal is to look for signs of illness, anemia, or infection and to assess overall fitness for surgery if needed. RCOG
Abdominal inspection and palpation
The abdomen is checked for a visible bulge and a firm or cystic mass. Gentle pressing can locate the upper edge of a large ovarian cyst and detect tenderness. RCOG
Bimanual pelvic exam
One hand in the vagina and one on the abdomen can feel an adnexal mass, its size, mobility, and tenderness. A mobile, smooth mass favors a benign or borderline lesion; a fixed, nodular mass raises concern. RCOG
Rectovaginal exam
This helps assess the uterosacral ligaments and cul-de-sac for nodules or implants. It also helps evaluate mobility and fixation. RCOG
Assessment for ascites (fluid)
Shifting dullness or a fluid wave on abdominal exam can suggest ascites. Ascites is less common in borderline disease but can occur, especially with serous implants. NCBI

B) Manual bedside maneuvers

Mass mobility (“ballottement”)
Gentle side-to-side movement during pelvic exam helps judge whether the ovary is mobile. Restricted mobility can hint at adhesions or implants that need careful imaging and surgical planning. RCOG
Tenderness mapping
Systematic gentle pressure identifies the most painful area. Marked focal tenderness raises concern for torsion or rupture and speeds imaging or surgery. RCOG
Cough/Valsalva comparison
Asking the patient to cough can help distinguish a hernia (which becomes more obvious) from a deep pelvic mass (which usually does not). This is a quick bedside differentiation if the bulge is near the groin or lower abdomen. RCOG

C) Laboratory and pathological tests

Serum CA-125
CA-125 can be normal or only mildly raised in many borderline tumors, but it is still useful in the overall picture. High levels are not specific and can rise in many benign conditions. isuog.org
HE4 and the ROMA algorithm
HE4 combined with CA-125 (ROMA) helps assign risk level for an adnexal mass. It guides referral to a gynecologic oncology center when risk is high. isuog.org
CEA and CA19-9 (especially for mucinous tumors)
Raised CEA or CA19-9 can occur in mucinous ovarian tumors and helps differentiate from other types or from gastrointestinal sources when imaging is unclear. Meridian
β-hCG
A pregnancy test is essential in reproductive-age patients to avoid imaging or surgery that could affect pregnancy and to consider other diagnoses. RCOG
CBC, CMP, and coagulation profile
These are pre-operative safety labs. They check for anemia, kidney or liver issues, and bleeding risk. RCOG
Intra-operative frozen section
During surgery, the pathologist can examine a small sample quickly. Frozen section can suggest “borderline” versus “benign” versus “invasive,” but final diagnosis still depends on full, permanent sections with extensive sampling. NCBI
Definitive histopathology with WHO criteria
The final diagnosis depends on careful microscopic review of the entire tumor and any implants, looking for epithelial atypia without stromal invasion. This step defines the tumor as “borderline.” whobluebooks.iarc.who.int+1
Immunohistochemistry and molecular tests
Markers like PAX8, CK7/CK20, ER/PR, and mutations such as KRAS (common in mucinous) or BRAF (seen in some serous borderline) can support classification and exclude metastasis from the GI tract. Meridian

D) Electrodiagnostic test

Electrocardiogram (ECG) – pre-operative safety, not tumor diagnosis
There are no electrodiagnostic tests that diagnose ovarian borderline tumors directly. An ECG is used to check heart safety before anesthesia if surgery is planned. RCOG

E) Imaging tests

Transvaginal ultrasound (TVUS) with IOTA Simple Rules
Ultrasound is the first-line test. The IOTA rules use simple features (e.g., papillary projections, ascites, solid parts) to flag high-risk masses or to reassure when features look benign. Borderline tumors often show multilocular cysts with papillary areas. Obstetrics & Gynecology+2Radiopaedia+2
Color Doppler ultrasound
Doppler can show blood flow in papillary areas. Higher vascularity can raise suspicion. It is part of the ultrasound risk assessment. isuog.org
MRI pelvis (with contrast) and targeted CT of abdomen/pelvis
MRI helps when ultrasound is indeterminate and maps internal septa, mural nodules, and hemorrhage. CT is useful for suspected spread, implants, omental disease, or when planning surgery. Chest imaging may be added if implants are suspected. Staging follows FIGO principles used for ovarian epithelial tumors. esgo.org+2Obstetrics & Gynecology+2

Non-pharmacological treatments (therapies & other measures)

(Note: BOT care is surgery-first; items below cover peri-operative choices, recovery, symptom care, and lifestyle. These are supportive, not cancer-killing, unless noted. Evidence notes are added simply for clarity.)

Comprehensive surgical staging
What it is: Removal of the affected ovary/tube (or cyst in select cases), inspection of the abdomen, washings, biopsies, and omentum assessment by a gynecologic oncologist.
Purpose: Accurately tell the extent of disease, remove visible tumor, and guide follow-up.
Mechanism: Physical removal and pathological mapping lower residual disease risk and mis-staging.
Evidence note: Surgery is the cornerstone of BOT management; adjuvant chemo/radiation hasn’t shown benefit in typical cases. NCBI+1
Fertility-sparing surgery (FSS) when appropriate
What it is: Cystectomy or unilateral salpingo-oophorectomy with careful staging, preserving the uterus and the other ovary.
Purpose: Maintain fertility while controlling disease.
Mechanism: Removes tumor bulk and leaves reproductive organs when safe.
Evidence note: FSS is acceptable for many early BOTs; pregnancy outcomes are often favorable; completion surgery after child-bearing is debated across guidelines. PMC+2PubMed+2
Completion surgery after child-bearing (individualized)
What it is: Removing the remaining ovary ± uterus after finishing family planning.
Purpose: Reduce recurrence risk in select patients.
Mechanism: Eliminates residual at-risk tissue.
Evidence note: NCCN suggests completion surgery after FSS for BOT; other groups recommend individualization—discuss risks/benefits. PubMed
Laparoscopic approach (when feasible)
What it is: Keyhole surgery by experienced surgeons.
Purpose: Faster recovery, less pain, shorter stay.
Mechanism: Minimally invasive access reduces tissue trauma.
Evidence note: Laparoscopy is preferred in many cases if spillage is avoided and staging needs are met. exxcellence.org
Open (laparotomy) approach (selected cases)
What it is: Midline incision for large masses or complex staging.
Purpose: Safe handling of huge tumors, en bloc removal, and thorough staging.
Mechanism: Direct exposure for complex procedures; reduces rupture risk in giant masses.
Evidence note: Choice depends on size, adhesions, and surgeon’s plan. exxcellence.org
Avoidance of unnecessary ovarian cryopreservation
What it is: Not freezing ovarian tissue when contamination risk exists.
Purpose: Prevent re-introducing disease.
Mechanism: Reduces potential malignant cell re-implantation.
Evidence note: Experts caution against cryopreservation in BOT due to contamination risk. ScienceDirect
Enhanced Recovery After Surgery (ERAS) pathway
What it is: Standardized pre-/post-op diet, fluids, mobilization, and pain control.
Purpose: Faster recovery and fewer complications.
Mechanism: Multimodal protocols reduce surgical stress.
Evidence note: Widely supported across gynecologic oncology surgery care pathways. JNCCN
Pelvic floor and core rehabilitation
What it is: Guided exercises after healing.
Purpose: Improve pelvic comfort, bowel/bladder function, and mobility.
Mechanism: Strengthens supportive muscles and restores function after surgery.
Evidence note: Recommended in survivorship to improve quality of life. JNCCN
Nutrition counseling (post-op and survivorship)
What it is: Balanced diet, protein optimization, and weight management.
Purpose: Support healing and general health.
Mechanism: Adequate macro/micronutrients aid tissue repair and energy.
Evidence note: Standard supportive care; no diet cures BOT. JNCCN
Symptom-guided pain management (non-opioid first-line)
What it is: Acetaminophen/NSAIDs per clinician guidance; short opioid courses only if needed.
Purpose: Comfort while minimizing opioid exposure.
Mechanism: Multimodal analgesia targets different pain pathways.
Evidence note: ERAS encourages non-opioid multimodal regimens. JNCCN
Psychological support and counseling
What it is: Coping skills, anxiety/depression support, fertility/menopause counseling.
Purpose: Reduce distress and improve adherence and QoL.
Mechanism: Cognitive and supportive therapies buffer stress response.
Evidence note: Standard survivorship care recommendation. JNCCN
Sexual health counseling
What it is: Guidance for dyspareunia, libido, lubrication, and timing to resume intercourse after surgery.
Purpose: Restore sexual well-being.
Mechanism: Education, lubricants, and pelvic PT.
Evidence note: Routine in gynecologic oncology survivorship. JNCCN
Fertility planning with reproductive endocrinology
What it is: Timed conception, oocyte/embryo strategies (not tissue cryo), genetic counseling if indicated.
Purpose: Optimize safe pregnancy attempts.
Mechanism: Individualized timing and monitoring after FSS.
Evidence note: Many achieve pregnancy post-FSS; coordination improves outcomes. PMC
Surveillance strategy
What it is: Scheduled visits, exam, ultrasound as indicated, and tumor markers if appropriate.
Purpose: Catch recurrences early.
Mechanism: Structured follow-up over years.
Evidence note: PDQ outlines BOT follow-up principles. Cancer.gov
Smoking cessation
What it is: Stop tobacco use.
Purpose: Better healing and lower complications and overall cancer risks.
Mechanism: Improves oxygenation and immune function; reduces thrombosis risk.
Evidence note: Standard surgical wellness guidance. JNCCN
Safe physical activity progression
What it is: Gradual walking → light strengthening after clearance.
Purpose: Reduce fatigue, enhance mood, prevent deconditioning.
Mechanism: Restores aerobic capacity and muscle strength.
Evidence note: Core survivorship advice. JNCCN
Management of early menopause (if both ovaries removed)
What it is: Discussion of vasomotor, bone, and heart health; HRT only if appropriate.
Purpose: Protect long-term health and quality of life.
Mechanism: Symptom-guided measures ± hormones when safe.
Evidence note: Individualized per risk profile. JNCCN
Bowel regimen and adhesiolysis prevention measures
What it is: Stool softeners, hydration, and gentle diet advance; meticulous surgical technique.
Purpose: Prevent ileus/constipation and adhesion-related pain.
Mechanism: Reduces GI stress and adhesions.
Evidence note: Standard post-op care. JNCCN
Second-opinion pathology review
What it is: Expert gynecologic pathologist confirmation.
Purpose: Distinguish BOT from invasive or benign variants.
Mechanism: Specialized histology review reduces misclassification.
Evidence note: Impacts treatment path and prognosis. Dove Medical Press
Patient education & red-flag awareness
What it is: Clear instructions on symptoms that need prompt care.
Purpose: Early detection of recurrence or complications.
Mechanism: Timely reporting leads to earlier evaluation.
Evidence note: Recommended in PDQ patient materials. Cancer.gov

Drug treatments

Important medical note: For typical BOT, systemic drug therapy is usually not indicated; surgery alone is standard. The drugs below are FDA-approved for epithelial ovarian cancer or related settings, not specifically for routine BOT. They may be relevant only in rare scenarios (e.g., transformation to invasive carcinoma, coexisting invasive disease, or clinical trials). Dosing must be individualized by your oncology team. NCBI

Paclitaxel (Taxol/Paclitaxel Injection)
Class: Antimicrotubule (taxane). Typical dosing (ovarian CA): 175 mg/m² IV over 3 h q3wk with carboplatin; other schedules exist. When used: First-line or recurrent epithelial ovarian cancer (not routine for BOT). Purpose/Mechanism: Stabilizes microtubules → blocks mitosis → tumor cell death. Side effects: Neutropenia, neuropathy, alopecia, hypersensitivity, mucositis. Label evidence: Ovarian carcinoma trials and adverse-event profile are detailed in FDA labeling. FDA Access Data+2FDA Access Data+2
Carboplatin (Paraplatin/Carboplatin)
Class: Platinum (DNA cross-linker). Typical dosing: AUC-based (e.g., AUC 5–6) IV q3wk with paclitaxel. When used: Backbone with taxanes for ovarian carcinoma; not routine for BOT. Mechanism: DNA crosslinks → apoptosis. Side effects: Myelosuppression, nausea, neuropathy (less than cisplatin), renal effects. Label evidence: Indicated in ovarian cancer; dosing/risks in FDA label. FDA Access Data+1
Cisplatin
Class: Platinum. Typical dosing: e.g., 75 mg/m² IV q3wk with paclitaxel (alternative to carboplatin). When used: Ovarian regimens historically; less used than carboplatin due to toxicity. Mechanism: DNA crosslinking. Side effects: Nephrotoxicity, ototoxicity, neuropathy, nausea. Label evidence: FDA-approved uses include ovarian carcinoma combinations. FDA Access Data
Bevacizumab (Avastin)
Class: Anti-VEGF monoclonal antibody. Typical dosing: 15 mg/kg IV q3wk (varies by regimen). When used: Selected epithelial ovarian cancer settings; avoid with bowel involvement/obstruction risk. Mechanism: Blocks VEGF → anti-angiogenesis. Side effects: Hypertension, proteinuria, bleeding, wound complications, GI perforation/fistula risks. Label evidence: Ovarian-specific safety cautions in FDA label. FDA Access Data
Olaparib (Lynparza)
Class: PARP inhibitor. Typical dosing: 300 mg orally twice daily (tablets). When used: Maintenance for recurrent or first-line HRD-positive advanced epithelial ovarian cancer after response to platinum; sometimes combined with bevacizumab. Mechanism: PARP inhibition → synthetic lethality in HRD/BRCA-mutant cells. Side effects: Anemia, fatigue, nausea; rare MDS/AML. Label evidence: Indications and dosing in FDA label. FDA Access Data
Niraparib (Zejula)
Class: PARP inhibitor. Typical dosing: 200–300 mg orally once daily; first-line or recurrent maintenance after platinum response (see label for starting dose by weight/platelets). Side effects: Thrombocytopenia, anemia, hypertension, fatigue. Label evidence: Updated ovarian maintenance indications in 2025 label. FDA Access Data
Rucaparib (Rubraca)
Class: PARP inhibitor. Typical dosing: 600 mg orally twice daily (older labeling; verify current). When used: Maintenance in recurrent epithelial ovarian cancer after platinum response; historical treatment indication in BRCA-mutated disease. Side effects: Elevated liver enzymes, anemia, fatigue, nausea. Label evidence: ARIEL3 maintenance data and indications in FDA label. FDA Access Data+1
Docetaxel
Class: Taxane. Typical dosing: 75 mg/m² IV q3wk with platinum in some ovarian regimens. When used: Alternative to paclitaxel in epithelial ovarian cancer. Mechanism: Microtubule stabilization. Side effects: Neutropenia, fluid retention, neuropathy. Label evidence: FDA-approved in multiple cancers; used in ovarian regimens per labels/compendia. FDA Access Data
Topotecan
Class: Topoisomerase-I inhibitor. Typical dosing: 1.5 mg/m² IV daily ×5 q3wk (common). When used: Recurrent epithelial ovarian cancer. Mechanism: DNA replication interference via topo-I inhibition. Side effects: Myelosuppression, fatigue, GI upset. Label evidence: Ovarian indication included in FDA label. JNCCN
Pegylated liposomal doxorubicin (PLD)
Class: Anthracycline. Typical dosing: 40–50 mg/m² IV q4wk. When used: Recurrent ovarian cancer. Mechanism: DNA intercalation and free radical damage; pegylation alters pharmacokinetics. Side effects: Hand-foot syndrome, mucositis, myelosuppression, cardiotoxicity risk. Label evidence: Ovarian indication in FDA label. JNCCN
Gemcitabine
Class: Antimetabolite. Typical dosing: 800–1000 mg/m² IV days 1 & 8 q21d ± carboplatin. When used: Recurrent ovarian cancer combinations. Mechanism: Nucleotide analog → DNA synthesis block. Side effects: Myelosuppression, transaminase elevations. Label evidence: Compendia-listed; used in ovarian regimens. JNCCN
Cyclophosphamide
Class: Alkylator. Typical dosing: Various IV/oral regimens; largely historical in ovarian cancer. When used: Selected recurrent settings. Mechanism: DNA crosslinks. Side effects: Myelosuppression, cystitis, GI, alopecia. Label evidence: Longstanding use; not BOT-specific. JNCCN
Ifosfamide
Class: Alkylator. Typical dosing: Variable inpatient schedules with mesna. When used: Rarely in selected ovarian regimens. Mechanism: DNA crosslinking. Side effects: Myelosuppression, encephalopathy, hemorrhagic cystitis. Label evidence: Historical/compendia use. JNCCN
Bevacizumab + paclitaxel/carboplatin (combination)
What it adds: Anti-angiogenic activity layered onto platinum-taxane backbone in epithelial ovarian cancer. Cautions: Wound healing and GI perforation risks; avoid with bowel involvement/obstruction. Label evidence: Safety cautions and ovarian context on FDA label. FDA Access Data
Mirvetuximab soravtansine-gynx (ELAHERE)
Class: FRα-directed antibody-drug conjugate. Typical dosing: 6 mg/kg AIBW IV q3wk (see label). When used: FRα-positive platinum-resistant epithelial ovarian cancer. Mechanism: Antibody delivers DM4 microtubule inhibitor inside FRα-expressing cells. Side effects: Ocular toxicity, fatigue, GI, myelosuppression. Label evidence: FDA label details mechanism and safety. FDA Access Data+1
Trabectedin (± PLD)
Class: DNA minor-groove binder. Typical dosing: 1.1 mg/m² 24-h IV q3wk with PLD in some regions. When used: Recurrent ovarian cancer (regional approvals; US availability varies). Mechanism: Transcription-coupled NER interference. Side effects: Transaminase rises, myelosuppression. Label evidence: Use differs by jurisdiction; consult local labeling. JNCCN
Pemetrexed (selected recurrent settings)
Class: Antifolate. Typical dosing: 500 mg/m² IV q3wk ± platinum. Mechanism: Inhibits folate-dependent enzymes. Side effects: Myelosuppression, mucositis; needs folate/B12 support. Label evidence: Compendia-supported in some ovarian regimens. JNCCN
Etoposide (oral/IV)
Class: Topoisomerase-II inhibitor. Typical dosing: Various; sometimes oral for platinum-resistant disease. Mechanism: DNA strand breakage via topo-II. Side effects: Myelosuppression, mucositis, alopecia. Label evidence: Historical use; check current compendia. JNCCN
Tamoxifen / Aromatase inhibitors (e.g., letrozole)
Class: Endocrine therapy. Typical dosing: Tamoxifen 20 mg daily; letrozole 2.5 mg daily (off-label in ovarian). When used: Hormone-receptor–positive low-grade serous carcinoma; not standard for BOT. Mechanism: ER blockade or estrogen synthesis suppression. Side effects: Hot flashes, thrombosis risk (tamoxifen); arthralgia/bone loss (AIs). Evidence: Off-label; consider in specialized settings. JNCCN
Clinical trial agents (e.g., MEK/RAF/FAK pathway inhibitors in LGSOC)
What this means: Targeted drugs for low-grade serous carcinoma (not BOT) in trials or recent approvals; pathway relevance differs. Use: Trial-directed only. Evidence: Rapidly evolving; discuss with your oncologist. ScienceDirect

Dietary molecular supplements

Safety first: Discuss supplements with your clinician; some interact with surgery, chemo (if ever used), or other medicines.

Protein (whey/plant protein) – Supports wound healing and lean mass; typical 20–30 g per serving as advised. Works by providing essential amino acids for tissue repair.
Omega-3 fatty acids (EPA/DHA) – 1–2 g/day can help general inflammation and recovery; mechanisms include mediators that resolve inflammation.
Vitamin D3 – Correct deficiency (often 1000–2000 IU/day or per labs) to support bone/immune health after oophorectomy in some patients.
Calcium – 1000–1200 mg/day dietary ± supplement if intake is low; supports bone health if ovarian hormones are reduced.
Iron (if deficient) – Dose per labs; restores hemoglobin after peri-operative loss; mechanism: hemoglobin synthesis.
Vitamin B12 & Folate (if low) – Normalize methylation and red cell production; dose per deficiency.
Probiotics – Can support bowel regularity post-op; mechanism: microbiome modulation; choose regulated products.
Magnesium – Helps constipation/cramps; typical 200–400 mg/day; mechanism: smooth muscle relaxation.
Zinc – Short-term for wound healing if deficient; mechanism: enzymatic cofactor in repair.
Fiber (psyllium, inulin) – Gradual titration supports bowel habits; mechanism: stool bulk and microbiota effects.
(These are general wellness measures; no supplement is proven to prevent or cure BOT.) JNCCN

Drugs forimmunity booster / regenerative / stem-cell

Medical caution: There are no FDA-approved “stem-cell drugs” or immune boosters to treat BOT. Below are clinical-care medicines sometimes used for support, not for BOT control.

Influenza & COVID-19 vaccines – Dosing per national schedules. Function: reduce infection risk during recovery; mechanism: antigen-specific immunity.
Erythropoiesis-stimulating agents (when indicated) – Dose per label; function: treat specific anemia causes; mechanism: EPO-receptor activation.
G-CSF (filgrastim/pegfilgrastim) – Used only if a cytotoxic regimen is given (rare in BOT); function: support neutrophils; mechanism: marrow stimulation.
Vitamin D repletion (per labs) – Function: bone/immune support; mechanism: nuclear receptor signaling.
Bisphosphonates (if early menopause with bone loss) – Dose per label; function: protect bone; mechanism: osteoclast inhibition.
HRT (select patients only) – Dose individualized; function: relieve severe menopausal symptoms after bilateral oophorectomy; mechanism: estrogen/progestin replacement when safe. JNCCN

Surgeries (what is done and why)

Unilateral salpingo-oophorectomy (USO) – Remove one ovary and tube; why: standard for unilateral BOT with fertility desire. PMC
Cystectomy (selected serous BOTs) – Remove the cyst wall only; why: preserve more ovarian tissue; higher recurrence than USO in mucinous BOTs. ecancer
Bilateral salpingo-oophorectomy (BSO) – Remove both ovaries/tubes; ± hysterectomy; why: definitive option when fertility not desired or for bilateral disease. exxcellence.org
Omentectomy and peritoneal biopsies – why: staging, detect implants, clear visible disease. JNCCN
Resection of implants/adhesiolysis – why: remove visible peritoneal implants when present and improve symptoms. JNCCN

Preventions

Know family history; seek genetics if strong history of ovarian/breast cancer. JNCCN
Regular gynecologic care; prompt evaluation of persistent bloating/pelvic pain. Cancer.gov
Avoid smoking; it worsens surgical outcomes. JNCCN
Healthy weight and activity for surgical recovery and overall risk reduction. JNCCN
Discuss contraceptive choices; OCPs reduce invasive epithelial ovarian cancer risk (population-level): context with your clinician. JNCCN
Limit talc use in genital area pending ongoing risk debates; choose alternatives. JNCCN
Manage endometriosis proactively (if present) with specialist care. JNCCN
Timely surgery for complex/persistent ovarian cysts per guidelines. JNCCN
Optimize vitamin D and bone health if ovaries removed. JNCCN
Stay engaged in long-term follow-up after BOT surgery. Cancer.gov

When to see a doctor (red flags)

See your gynecologist or oncology team promptly for: new or worsening bloating or abdominal swelling; pelvic or abdominal pain; early fullness/poor appetite; new constipation or persistent bowel changes; unexpected vaginal bleeding; unintentional weight loss; fever after surgery; severe nausea/vomiting; new shortness of breath; or any sudden, severe symptom after surgery such as calf swelling or chest pain. These signs can reflect recurrence, complications, or unrelated but important conditions that need evaluation. Cancer.gov

What to eat and what to avoid

Eat more:

Lean proteins (fish, poultry, legumes) for healing.
Colorful fruits/vegetables for fiber and micronutrients.
Whole grains for steady energy and bowel regularity.
Healthy fats (nuts, olive oil) for satiety and heart health.
Probiotic foods (yogurt/kefir) to support gut function.

Limit/Avoid:

Highly processed foods and excess sugars (fatigue swings).
Very salty foods if swelling/blood pressure issues.
Excess alcohol (healing and medication interactions).
Herbal products with bleeding risk near surgery (e.g., high-dose garlic, ginkgo) unless cleared by your team.
Unvetted “cancer cure” supplements; none cure BOT. JNCCN

FAQs

1) Is a borderline tumor cancer?
It’s in between benign and cancer. It has abnormal cells but little or no invasion, so it behaves much less aggressively than ovarian cancer. Surgery is the main treatment. Dove Medical Press

2) Do I need chemotherapy or radiation?
Typically no. Studies and national summaries show no proven benefit for adjuvant chemo or radiation in usual BOT. Care is individualized if high-risk features appear. NCBI

3) Can I keep my fertility?
Often yes, with carefully staged fertility-sparing surgery; many patients later conceive. Decisions are individualized. PMC

4) Will I need completion surgery after having children?
Some guidelines suggest it; others advise individualizing. Discuss your pathology, age, and goals. PubMed

5) What is my long-term outlook?
Excellent for most; 10-year survival is high. Regular follow-up matters because a minority recur. Dove Medical Press

6) What are “implants,” and why do they matter?
Small deposits on peritoneal surfaces. Invasive implants increase risk, changing decisions and follow-up plans. Dove Medical Press

7) Is cystectomy safe?
It can be for selected serous BOTs, but mucinous BOTs have higher recurrence; many experts favor USO over cystectomy in mucinous cases. ecancer

8) What tests will I have after surgery?
Physical exams, symptom review, pelvic imaging as needed, and selective tumor markers based on subtype and plan. Cancer.gov

9) How often are follow-ups?
Schedules vary; expect more frequent visits in the first years, then less often long-term. Cancer.gov

10) Can diet or supplements cure BOT?
No. Nutrition supports recovery and well-being but does not treat BOT. JNCCN

11) If my pathology changes to invasive cancer later, do options change?
Yes. Treatments then follow epithelial ovarian cancer guidelines (e.g., platinum-taxane, PARP inhibitors, etc.). JNCCN

12) Is laparoscopic surgery safe for large cysts?
It can be with experienced surgeons, but open surgery may be chosen to avoid rupture and allow full staging. exxcellence.org

13) Should I get a second pathology review?
Yes—helpful because treatment choices hinge on an accurate BOT subtype diagnosis. Dove Medical Press

14) Are there screening tests to catch BOT early?
No routine population screening is recommended; see a clinician promptly for persistent symptoms. Cancer.gov

15) Can hormonal therapy treat BOT?
Not standard. Endocrine therapies are used for some low-grade serous carcinomas, which are different from BOT. JNCCN

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 30, 2025.

PDF Documents For This Disease Condition

References

SaveSavedRemoved 0